UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 10, 2026**

PHARMACYTE BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada	**001-40699**	**62-1772151**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3960 Howard Hughes Parkway, Suite 500 **Las Vegas, Nevada**	**89169**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(917) 595-2850**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, Par Value $0.0001 Per Share	PMCB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.03 Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 10, 2026, PharmaCyte Biotech, Inc., a Nevada corporation (the "Company"), filed with the Secretary of State of the State of Nevada a certificate of amendment (the "Certificate of Amendment") to its Articles of Incorporation, as amended, to effect a reverse stock split of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of 1-for-19 (the "Reverse Stock Split"), with an effective date of November 12, 2026. The Reverse Stock Split was approved by the Company's stockholders at the Company's annual meeting of stockholders held on March 30, 2026, which authorized the Company's board of directors to effect a reverse stock split at a ratio between 1-for-1.1 and 1-for-100. Pursuant to the Certificate of Amendment, the Reverse Stock Split became effective as of 4:01 p.m. Eastern Time on November 12, 2026 (the "Effective Time"), and the Common Stock began trading on a split-adjusted basis at the open of trading on The Nasdaq Capital Market on November 13, 2026. At the Effective Time, every nineteen (19) shares of the Company's issued and outstanding Common Stock were automatically combined and converted into one (1) share of Common Stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, warrants and convertible securities, and to the number of shares issued and issuable under the Company's equity incentive plans. No change was made to the number of shares of Common Stock authorized under the Company's Articles of Incorporation, as amended. Any stockholder who would otherwise be entitled to a fractional share of Common Stock created as a result of the Reverse Stock Split is entitled to receive a cash payment in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of Common Stock on The Nasdaq Capital Market on the trading day immediately prior to the Effective Time, as adjusted for the Reverse Stock Split.

Following the Reverse Stock Split, the shares of Common Stock continue to trade on The Nasdaq Capital Market under the symbol "PMCB." The new CUSIP number for the Common Stock following the Reverse Stock Split is 71715X302.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 8.01 Other Events.

On November 11, 2026, the Company issued a press release announcing the Reverse Stock Split. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
3.1	Certificate of Amendment to the Articles of Incorporation, as amended, of PharmaCyte Biotech, Inc.
99.1	Press Release issued by PharmaCyte Biotech, Inc., dated November 11, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMACYTE BIOTECH, INC.

Date: November 13, 2026

By: /s/ Joshua N. Silverman
Name: Joshua N. Silverman
Title: Chief Executive Officer and President

Exhibit 3.1

CERTIFICATE OF AMENDMENT TO
ARTICLES OF INCORPORATION OF
PHARMACYTE BIOTECH, INC.
a Nevada corporation
(Pursuant to NRS 78.385 and 78.390)

PharmaCyte Biotech, Inc., a Nevada corporation (the "Corporation"), hereby certifies as follows:

1. The name of the corporation is PharmaCyte Biotech, Inc.

2. The Articles of Incorporation of the Corporation, as amended (the "Articles"), have been amended as follows:

Article IV of the Articles is hereby amended by inserting the following paragraph as the first paragraph of Article IV:

"Upon the effectiveness of this Certificate of Amendment (the "Effective Time"), every nineteen (19) shares of common stock, par value $0.0001, of the Corporation (the "Common Stock"), issued and outstanding immediately prior to the Effective Time, shall automatically and without any further action on the part of the Corporation or any holder thereof be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock (the "Reverse Stock Split"). The par value of the Common Stock following the Reverse Stock Split shall remain $0.0001. No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu of any fractional share to which a holder would otherwise be entitled as a result of the Reverse Stock Split, such holder shall be entitled to receive a cash payment equal to the fraction of a share to which such holder would otherwise be entitled multiplied by the closing price of the Common Stock as reported on The Nasdaq Stock Market on the day of the Effective Time. The total number of shares of capital stock that the Corporation is authorized to issue shall not be changed by the Reverse Stock Split or this Certificate of Amendment and shall remain two hundred and ten million (210,000,000) shares, consisting of two hundred million (200,000,000) shares of Common Stock, par value $0.0001, and ten million (10,000,000) shares of preferred stock, par value $0.0001. Each certificate that immediately prior to the Effective Time represented shares of Common Stock shall thereafter represent the number of whole shares of Common Stock into which the shares represented by such certificate shall have been combined as a result of the Reverse Stock Split, subject to the treatment of fractional share interests described above."

3. The stockholders of the Corporation approved the amendment with 5,067,304 votes, representing 68.96% of the votes cast on the proposal, voted in favor of the amendment at the annual meeting of stockholders held on March 30, 2026.

4. Effective date and time of filing: November 12, 2026, at 1:01 p.m. Pacific Time.

IN WITNESS WHEREOF, the undersigned has caused this Certificate of Amendment to the Articles of Incorporation to be executed by a duly authorized officer of the Corporation on this 10th day of November 2026.

PHARMACYTE BIOTECH, INC.

By: /s/ Joshua N. Silverman
Name: Joshua N. Silverman
Title: Chief Executive Officer and President

Exhibit 99.1

PharmaCyte Biotech, Inc. Announces Reverse Stock Split

PharmaCyte's common stock is expected to begin trading on a post-split adjusted basis on November 13, 2026

LAS VEGAS--(BUSINESS WIRE)—November 11, 2026—PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company"), today announced that the board of directors of the Company approved a 1-for-19 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders at the Company's annual meeting of the stockholders held on March 30, 2026. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on November 12, 2026. The Company's common stock will open for trading under a new CUSIP number 71715X 302 on The Nasdaq Capital Market on November 13, 2026, on a split-adjusted basis under the current ticker symbol "PMCB." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The 1-for-19 Reverse Split will automatically convert every nineteen (19) current shares of the Company's common stock into one (1) share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company's common stock following the Reverse Split will receive a cash payment in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of the Company's common stock on The Nasdaq Capital Market, on November 12, 2026 (the last trading day prior to the commencement of split-adjusted trading), as adjusted for the Reverse Split

The Reverse Split will reduce the number of shares of outstanding common stock from approximately 10,755,649 shares, the number of shares outstanding as of November 11, 2026, to approximately 566,087 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company's outstanding stock options, warrants and convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans.

Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company's transfer agent, Equiniti Trust Company, LLC, will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.

Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and effectiveness of the Reverse Split, the Company's ability to regain compliance with the Nasdaq minimum bid price and other listing requirements and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including statements regarding the Company's current objectives. These statements are based on the Company's current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additional information regarding these and other risks and uncertainties is contained in the Company's filings with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Investor Contact:
CORE IR
ir@pharmacyte.com

Media Contact:
Jules Abraham
CORE IR
Telephone: 917.885.7378
Email: julesa@coreir.com